JP2003505111A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003505111A5 JP2003505111A5 JP2001513645A JP2001513645A JP2003505111A5 JP 2003505111 A5 JP2003505111 A5 JP 2003505111A5 JP 2001513645 A JP2001513645 A JP 2001513645A JP 2001513645 A JP2001513645 A JP 2001513645A JP 2003505111 A5 JP2003505111 A5 JP 2003505111A5
- Authority
- JP
- Japan
- Prior art keywords
- tenascin
- nucleic acid
- nucleic acids
- candidate mixture
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 description 64
- 102000039446 nucleic acids Human genes 0.000 description 64
- 108020004707 nucleic acids Proteins 0.000 description 64
- 102000007000 Tenascin Human genes 0.000 description 31
- 108010008125 Tenascin Proteins 0.000 description 31
- 239000003446 ligand Substances 0.000 description 31
- 239000000203 mixture Substances 0.000 description 31
- 238000000034 method Methods 0.000 description 29
- 239000003550 marker Substances 0.000 description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 229920002477 rna polymer Polymers 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 3
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940056501 technetium 99m Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/364,902 US6232071B1 (en) | 1990-06-11 | 1999-07-29 | Tenascin-C nucleic acid ligands |
| US09/364,902 | 1999-07-29 | ||
| PCT/US2000/002167 WO2001009390A1 (en) | 1999-07-29 | 2000-01-28 | Tenascin-c nucleic acid ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003505111A JP2003505111A (ja) | 2003-02-12 |
| JP2003505111A5 true JP2003505111A5 (enExample) | 2007-03-01 |
Family
ID=23436596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001513645A Pending JP2003505111A (ja) | 1999-07-29 | 2000-01-28 | テネイシンｃの核酸リガンド |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US6232071B1 (enExample) |
| EP (1) | EP1198589B9 (enExample) |
| JP (1) | JP2003505111A (enExample) |
| KR (1) | KR100605072B1 (enExample) |
| CN (2) | CN100558411C (enExample) |
| AT (1) | ATE405675T1 (enExample) |
| AU (1) | AU767501C (enExample) |
| BG (1) | BG106361A (enExample) |
| BR (1) | BR0013170A (enExample) |
| CA (1) | CA2380473A1 (enExample) |
| CZ (1) | CZ2002365A3 (enExample) |
| DE (1) | DE60039986D1 (enExample) |
| DK (1) | DK1198589T3 (enExample) |
| EA (1) | EA004795B1 (enExample) |
| EE (1) | EE200200051A (enExample) |
| ES (1) | ES2310989T3 (enExample) |
| HK (1) | HK1048499B (enExample) |
| HR (1) | HRP20020186A2 (enExample) |
| HU (1) | HUP0202221A3 (enExample) |
| IL (2) | IL147872A0 (enExample) |
| MX (1) | MXPA02000819A (enExample) |
| NO (1) | NO20020424L (enExample) |
| NZ (2) | NZ516907A (enExample) |
| PL (1) | PL201637B1 (enExample) |
| RS (1) | RS50426B (enExample) |
| SK (1) | SK1222002A3 (enExample) |
| UA (1) | UA75578C2 (enExample) |
| WO (1) | WO2001009390A1 (enExample) |
| ZA (1) | ZA200200747B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6232071B1 (en) * | 1990-06-11 | 2001-05-15 | Gilead Sciences, Inc. | Tenascin-C nucleic acid ligands |
| US7005260B1 (en) * | 2000-01-28 | 2006-02-28 | Gilead Sciences, Inc. | Tenascin-C nucleic acid ligands |
| CA2328356A1 (en) | 1999-12-22 | 2001-06-22 | Itty Atcravi | Recreational vehicles |
| US7645743B2 (en) * | 1999-12-22 | 2010-01-12 | Altermune, Llc | Chemically programmable immunity |
| IL159053A0 (en) | 2001-05-25 | 2004-05-12 | Univ Duke | Modulators of pharmacological agents |
| AU2003247576A1 (en) * | 2002-06-18 | 2003-12-31 | Archemix Corp. | Aptamer-toxin molecules and methods for using same |
| US20040249130A1 (en) * | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
| US8039443B2 (en) * | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US10100316B2 (en) | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
| US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| US20080268478A1 (en) * | 2005-03-01 | 2008-10-30 | Cedars-Sinai Medical Center | Use of Eotaxin as a Diagnostic Indicator For Atherosclerosis and Vascular Inflammation |
| AR052741A1 (es) * | 2005-04-08 | 2007-03-28 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
| WO2008028688A2 (en) | 2006-09-08 | 2008-03-13 | Bayer Schering Pharma Aktiengesellschaft | Compounds and methods for 18f labeled agents |
| EP1897562A1 (en) * | 2006-09-08 | 2008-03-12 | Bayer Schering Pharma Aktiengesellschaft | Aptamers labelled with Gallium-68 |
| US20110136099A1 (en) | 2007-01-16 | 2011-06-09 | Somalogic, Inc. | Multiplexed Analyses of Test Samples |
| US8975026B2 (en) | 2007-01-16 | 2015-03-10 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| CA2696431C (en) * | 2007-07-17 | 2021-01-05 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| EP2036981A1 (en) * | 2007-09-12 | 2009-03-18 | Bayer Schering Pharma Aktiengesellschaft | Aptamers labeled with 18F |
| US8604184B2 (en) | 2009-05-05 | 2013-12-10 | The United States Of America As Represented By The Secretary Of The Air Force | Chemically programmable immunity |
| US8236570B2 (en) | 2009-11-03 | 2012-08-07 | Infoscitex | Methods for identifying nucleic acid ligands |
| US8841429B2 (en) | 2009-11-03 | 2014-09-23 | Vivonics, Inc. | Nucleic acid ligands against infectious prions |
| GB201114662D0 (en) | 2011-08-24 | 2011-10-12 | Altermune Technologies Llc | Chemically programmable immunity |
| CN102533772B (zh) * | 2011-12-12 | 2013-10-09 | 中国科学院武汉病毒研究所 | 一种抗hbv诱饵适体及其筛选方法 |
| BR112014014295A2 (pt) * | 2011-12-12 | 2017-06-13 | Isis Innovation | método para determinar um estado de artrite reumatoide, kit para a determinação o estado de artrite reumatoide erosiva de um indivíduo, usos de tenancina-c, e de uma determinação do nível de tenascina-c, e, métodos para tratar uma condição inflamatória, e uma artrite reumatoide |
| CN112007045A (zh) | 2012-07-13 | 2020-12-01 | 波涛生命科学有限公司 | 手性控制 |
| CN107058596A (zh) * | 2017-06-19 | 2017-08-18 | 上海市第十人民医院 | 一种与恶性胶质瘤诊断相关的标志物及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4434585A (en) | 1985-03-30 | 1986-10-23 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
| WO1989006694A1 (en) | 1988-01-15 | 1989-07-27 | Trustees Of The University Of Pennsylvania | Process for selection of proteinaceous substances which mimic growth-inducing molecules |
| US5496938A (en) * | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US5789157A (en) * | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
| US6127119A (en) * | 1990-06-11 | 2000-10-03 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands of tissue target |
| US6610841B1 (en) * | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
| US6232071B1 (en) * | 1990-06-11 | 2001-05-15 | Gilead Sciences, Inc. | Tenascin-C nucleic acid ligands |
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| AU1435492A (en) | 1991-02-21 | 1992-09-15 | Gilead Sciences, Inc. | Aptamer specific for biomolecules and method of making |
| US5683874A (en) * | 1991-03-27 | 1997-11-04 | Research Corporation Technologies, Inc. | Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence |
| US5582981A (en) * | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US5436132A (en) * | 1993-02-13 | 1995-07-25 | Amano Pharmaceutical Co., Ltd. | Quantitative determination of tenascin as glioma marker |
| US5859228A (en) * | 1995-05-04 | 1999-01-12 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| US6229002B1 (en) * | 1995-06-07 | 2001-05-08 | Nexstar Pharmaceuticlas, Inc. | Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
| PT957929E (pt) * | 1996-10-25 | 2006-06-30 | Gilead Sciences Inc | Complexos de ligandos de acido nucleico do factor de crescimento endotelial vascular |
| US6242246B1 (en) * | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
-
1999
- 1999-07-29 US US09/364,902 patent/US6232071B1/en not_active Expired - Fee Related
-
2000
- 2000-01-28 JP JP2001513645A patent/JP2003505111A/ja active Pending
- 2000-01-28 MX MXPA02000819A patent/MXPA02000819A/es not_active IP Right Cessation
- 2000-01-28 HU HU0202221A patent/HUP0202221A3/hu unknown
- 2000-01-28 RS YUP-64/02A patent/RS50426B/sr unknown
- 2000-01-28 CN CNB2004100629077A patent/CN100558411C/zh not_active Expired - Fee Related
- 2000-01-28 ES ES00911657T patent/ES2310989T3/es not_active Expired - Lifetime
- 2000-01-28 SK SK122-2002A patent/SK1222002A3/sk not_active Application Discontinuation
- 2000-01-28 BR BR0013170-9A patent/BR0013170A/pt not_active Application Discontinuation
- 2000-01-28 EE EEP200200051A patent/EE200200051A/xx unknown
- 2000-01-28 EA EA200200094A patent/EA004795B1/ru not_active IP Right Cessation
- 2000-01-28 PL PL353357A patent/PL201637B1/pl not_active IP Right Cessation
- 2000-01-28 DK DK00911657T patent/DK1198589T3/da active
- 2000-01-28 HK HK03100657.1A patent/HK1048499B/zh not_active IP Right Cessation
- 2000-01-28 UA UA2002021549A patent/UA75578C2/uk unknown
- 2000-01-28 IL IL14787200A patent/IL147872A0/xx active IP Right Grant
- 2000-01-28 AU AU33519/00A patent/AU767501C/en not_active Ceased
- 2000-01-28 NZ NZ516907A patent/NZ516907A/en unknown
- 2000-01-28 WO PCT/US2000/002167 patent/WO2001009390A1/en not_active Ceased
- 2000-01-28 AT AT00911657T patent/ATE405675T1/de not_active IP Right Cessation
- 2000-01-28 CN CNB008109796A patent/CN1164760C/zh not_active Expired - Fee Related
- 2000-01-28 DE DE60039986T patent/DE60039986D1/de not_active Expired - Lifetime
- 2000-01-28 KR KR1020027001167A patent/KR100605072B1/ko not_active Expired - Fee Related
- 2000-01-28 CA CA002380473A patent/CA2380473A1/en not_active Abandoned
- 2000-01-28 HR HR20020186A patent/HRP20020186A2/hr not_active Application Discontinuation
- 2000-01-28 CZ CZ2002365A patent/CZ2002365A3/cs unknown
- 2000-01-28 EP EP00911657A patent/EP1198589B9/en not_active Expired - Lifetime
- 2000-01-29 NZ NZ528077A patent/NZ528077A/en unknown
-
2001
- 2001-05-14 US US09/854,662 patent/US6596491B2/en not_active Expired - Fee Related
-
2002
- 2002-01-28 IL IL147872A patent/IL147872A/en not_active IP Right Cessation
- 2002-01-28 ZA ZA200200747A patent/ZA200200747B/xx unknown
- 2002-01-28 NO NO20020424A patent/NO20020424L/no not_active Application Discontinuation
- 2002-01-29 BG BG106361A patent/BG106361A/bg unknown
-
2003
- 2003-05-01 US US10/429,176 patent/US20040058884A1/en not_active Abandoned
-
2005
- 2005-12-13 US US11/300,662 patent/US20060105378A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003505111A5 (enExample) | ||
| EA004795B1 (ru) | Нуклеиновые кислоты-лиганды тенасцина-c | |
| AU1600499A (en) | Nucleic acid ligands of tissue target | |
| JP2004511250A (ja) | 前立腺特異的膜抗原に対する核酸リガンド | |
| EP3827082B1 (en) | Icam-1 aptamers, diagnostic and therapeutic uses thereof | |
| TW200812626A (en) | Aptamers labeled with 68GA | |
| KR100366525B1 (ko) | 금속착체및올리고뉴클레오티드로구성된접합체 | |
| JP7671279B2 (ja) | Ｃａ－ｉｘアプタマー並びにその診断的および治療的使用 | |
| WO1996040273A2 (en) | Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures | |
| CN118477186A (zh) | 一种靶向s2亚基的正电子发射断层显像评价治疗变异新冠病毒感染的方法 | |
| JP2004503214A5 (enExample) | ||
| CN112920248A (zh) | 放射性核素99mTc标记的LncRNA HOTAIR靶向探针、制备方法以及显像剂 | |
| JP2003502392A (ja) | 血液中の抗凝固性オリゴデオキシヌクレオチドアプタマーの寿命延長 |